Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine

Currently approximately 240 million surgical procedures are done worldwide on a yearly basis. lnguinal hernia repair is one of the most performed surgeries in ambulatory setting. Despite currently available analgesic drugs, post surgical pain management remains challenging in this group of patients, as the pain score appears inadequate (mean VAS of 5.8 +/- 1 .22 cm) one day after surgery with the use of common analgesics. Beside accounting for patient discomfort, pain is also a major contributor to prolonged length of hospital stay and is a health care quality indicator. With multimodal pain management the intention is to reduce pain with less side effects of analgesics. Multimodal pain management is the combination of different pharmacologic mechanisms of action, which work by acting at different sites within the central and peripheral nervous system, thereby having an additive or synergistic effect and reducing the necessity of opiates. With this in mind, a potential new target for analgesic drugs are group- ll metabotropic glutamate receptors subtypes (mGlu2 and mGlu3 receptors) localized in the spinal cord and other regions of the nociceptive system. Growing evidence from animal models show that activation of these receptors occur via the glutamate:cystein antiporter and can induce analgesia in models of inflammatory and neuropathic pain. They depress pain transmission at synapses between primary afferent fibers and second order sensory neurons on the dorsal horn of the spinal cord.

N-Acetylcysteine (NAC) is on the market since 1968 and is an over the counter available agent, mostly known for its role as mucolytic agent in cystic fibrosis and for the treatment of acetaminophen intoxication. lt is a safe agent with little to no side effects. Recent studies have shown NAC can inhibit nociceptive transmission in rats and in healthy humans.NAC can induce analgesia by activating the glutamate:cystein antiporter, causing endogenous activation of the mGlu2/3 receptors. Therefore, NAC can potentially become a cheap and safe additive in the multimodal pain management. However, evidence for usage of NAC in the context of multimodal pain management is still lacking. Only one available study in humans evaluated the effect of NAC in the perioperative setting. Despite being a randomised controlled trial, there are several limitations in this study; the study arms are too small and only morphine consumption is presented. Also, blinding might have not as good as suggested since oral NAC has a typical flavour and the placebo was lemonade.

Due to these limitations, still no answer on the question whether NAC can be an additive in current multimodal pain management is provided.

Objective of the study:

Primary Objective:

To evaluate the efficacy of intravenous NAC in comparison with placebo in terms of pain relief after unilateral inguinal hernia repair measured by a visual analogue scale (VAS 0-100) at day 1 after surgery.

Secondary Objective(s):

• Difference in pain scores between NAC and placebo direct after surgery, before discharge and in following 3 days postoperative.
• Difference in time before first pain medication is administered postoperative between NAC and placebo.
• Difference in total consumption of opiates in the hospital (mg) between NAC and placebo.
• Difference in time from surgery to discharge between NAC and placebo.
• Difference in postoperative pain medication at home necessary to reach adequate pain relief between NAC and placebo (acetaminophen / NSAID's/ opiates).
• lf there is a difference in 5, is there also a difference in adverse effects of pain medication (like nausea, obstipation) between NAC and placebo.

Inclusion criteria

• Subjects scheduled for laparoscopic unilateral inguinal hernia repair
• ASA 1 or2.
• Age >18 years.

Exclusion criteria

• Pregnancy or lactating
• Allergy to NAC
• History of chronic pain
• Use of opioids or neuropathic analgesics
• Use of NAC prior to trial (< 1 month of planned surgery)
• Alcoholism
• Diabetes Mellitus (insulin therapy)
• Asthma or Chronic Obstructive pulmonary Disease
• Known renal function disorders (MDRD <ô0)
• Known liver failure (bilirubin >1.Sx upper limit of normal)
• No written lC by patient